# Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Meropenem in Complicated Intraabdominal Infections

> **NCT01445678** · PHASE3 · COMPLETED · sponsor: **Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)** · enrollment: 494 (actual)

## Conditions studied

- Complicated Intra-abdominal Infection

## Interventions

- **DRUG:** CXA-201 and metronidazole
- **DRUG:** Meropenem

## Key facts

- **NCT ID:** NCT01445678
- **Lead sponsor:** Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12-23
- **Primary completion:** 2013-10-03
- **Final completion:** 2013-10-15
- **Target enrollment:** 494 (ACTUAL)
- **Last updated:** 2018-11-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01445678

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01445678, "Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Meropenem in Complicated Intraabdominal Infections". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01445678. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*